Helsinn Healthcare S.A. v. Par Pharmaceutical Companies, Inc.

I'll research this case before drafting.

Case Overview — Helsinn Healthcare S.A. v. Par Pharmaceutical Companies, Inc., No. 1:15-cv-00265-GMS (D. Del.)

Parties and product. Helsinn Healthcare S.A. is a privately held Swiss specialty pharmaceutical company (Lugano-Pazzallo) that markets Aloxi® (palonosetron hydrochloride) injection, a 5-HT₃ receptor antagonist approved in July 2003 for chemotherapy-induced and postoperative nausea and vomiting; it is the only 5-HT₃ antagonist approved for delayed CINV and was a very large revenue product (Helsinn's own PGR papers cite "over $3.6 billion in U.S. sales"). Helsinn was the co-plaintiff here alongside Roche Palo Alto LLC, the Roche/Syntex entity whose palonosetron intellectual property Helsinn licensed in 1998 and which is a co-assignee of the formulation patents. Both are operating companies — this is a brand-pharma Hatch-Waxman suit, not an NPE/PAE assertion. The defendants were Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc., the Woodcliff Lake, NJ generic-drug unit of Par Pharmaceutical (which Endo International was in the process of acquiring in 2015). Helsinn's theory was the standard § 271(e)(2) one: Par's ANDA, with a Paragraph IV certification, sought FDA approval to market generic palonosetron HCl IV solution (0.25 mg/5 mL and 0.075 mg/1.5 mL single-use vials) before the Orange Book patents expired. Per the docket's ANDA supplemental-information sheet, Helsinn received Par's Paragraph IV notice on February 11, 2015 (CourtListener docket, D.I. 1 & unnumbered ANDA sheet); the specific Par ANDA number is not disclosed in the public docket.

Patent asserted and technical sketch. This case record carries U.S. Patent No. 7,947,725 ("Liquid pharmaceutical formulations of palonosetron"), which issued May 24, 2011 from Application No. 11/388,268 (filed Mar. 24, 2006), claiming priority to PCT/EP04/000888 (Jan. 30, 2004) and U.S. Provisional 60/444,351 (Jan. 30, 2003); assignees Helsinn Healthcare S.A. and Roche Palo Alto LLC; inventors Calderari, Bonadeo, Cannella, Braglia, Braglia, Miksztal, Malefyt and Lee. One line: a shelf-stable aqueous palonosetron formulation defined by drug concentration, acidic pH, mannitol as tonicifier, and EDTA as stabilizer — asserted claim 2 in the parallel litigation reads on 0.05 mg/mL palonosetron HCl (free-base basis) at pH 4.5–5.5 with 0.005–1.0 mg/mL EDTA and ~10–80 mg/mL mannitol (claim text). One important caveat: the complaint (D.I. 1, filed Mar. 25, 2015, with Exhibits A–E) and the Rule 4 Report to the Commissioner (D.I. 4) swept in the whole Aloxi Orange Book family — the '724, '725, '424, '219 and '094 patents — so the '725 was pleaded in parallel with its siblings rather than as a stand-alone assertion. I could not locate a public document in this docket narrowing the case to the '725 alone; the case was dismissed before any claim narrowing.

Procedural posture, venue and why it matters. Filed March 25, 2015 in the District of Delaware and assigned to Judge Gregory M. Sleet (D.I. 1, reassignment order Apr. 1, 2015). Par was served July 21, 2015 and then obtained a chain of stipulated extensions of its answer deadline (Aug. 11 → Sept. 11 → Oct. 12 → Nov. 13 → Dec. 14, 2015; D.I. 9–13), so issue was never joined: the FJC Integrated Database records the disposition as "voluntarily dismissed," procedural progress "no court action (before issue joined)," terminated Dec. 3, 2015 (termination date in this case record: Dec. 2, 2015, the date of the notice). Helsinn and Roche filed a Notice of Voluntary Dismissal on December 2, 2015 (D.I. 14), followed by the Rule 4 report on Dec. 9, 2015 (FJC IDB record). Venue mattered strategically: Delaware was where Helsinn ran a parallel wave of Aloxi ANDA suits against later filers (Cipla, Hospira, Fresenius, and others, 2013–2016, all before Judge Sleet), separate from its lead Aloxi case in

I'll research this case across court records, PTAB proceedings, and legal press.

Helsinn Healthcare S.A. v. Par Pharmaceutical Companies, Inc., No. 1:15-cv-00265 (D. Del.)

Sourcing note up front. The docket number for this case is 1:15-cv-00265-GMS (Judge Gregory M. Sleet), not the number implied by some aggregator records; the companion Delaware case filed the same day is Helsinn Healthcare S.A. v. Hospira, Inc., No. 1:15-cv-00264-GMS. The available docket is short (15 entries). Dates below are from RECAP/CourtListener and the FJC Integrated Database; I flag anything I could not independently source.

Also note a metadata discrepancy worth correcting in the case file: although the case summary lists only the '725 patent, the Complaint's Report to the Commissioner (D.I. 4, 2015-03-25) lists five patents — U.S. Patent Nos. 7,947,724; 7,947,725; 7,960,424; 8,598,219; and 8,729,094 — all Orange Book–listed for ALOXI® (palonosetron HCl injection, eq. 0.25 mg base/5 mL).

---

1. Filing and initial pleadings

• 2015-02-11 — Date Helsinn/Roche received Par's Paragraph IV notice letter (per the ANDA supplemental information sheet, D.I. 3). This is the Hatch-Waxman 45-day clock trigger; patent expiry stated as 2024-01-30, thirty-month stay deadline 2017-08-11.
• 2015-03-23 — Helsinn Healthcare S.A. and Roche Palo Alto LLC file a parallel action against the same Par entities in D.N.J., No. 3:15-cv-02078 (MLC/DEA) (Cooper, J.), asserting the same patent family.
• 2015-03-25 — Complaint filed in D. Del., No. 1:15-cv-00265, by Helsinn Healthcare S.A. and Roche Palo Alto LLC against Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc., alleging infringement under 35 U.S.C. § 271(e)(2) based on Par's ANDA. Filed with Exhibits A–E (D.I. 1). Rule 7.1 disclosure statements filed same day by Helsinn (D.I. 5) and Roche Palo Alto (D.I. 6). Case assigned to Judge Sleet; summonses issued 2015-03-26.
• 2015-07-21 — Service effected on Par Pharmaceutical, Inc. (D.I. 7, 8); answer due 2015-08-11.
• 2015-08-11 / 2015-09-10 / 2015-10-09 / 2015-11-13 — Four successive stipulated extensions of Par's response deadline (D.I. 9, 10, 11, 12), pushing the answer date from 2015-08-11 to 2015-12-14.
• 2015-11-17 — Order (D.I. 13) granting the fourth extension but warning: "The Court will grant no further extensions."
• No answer, counterclaims, or Rule 12 motion was ever filed in Delaware. Par's counterclaims (against Helsinn and Roche Palo Alto as counter-defendants) were pleaded only in the D.N.J. action, where Par appeared through Gerald Krovatin and Arnold B. Calmann and filed a corporate disclosure statement on 2015-11-09 (D.N.J. D.I. 21).

2. Pre-trial motions of substance

• None. The Delaware case never reached a motion to dismiss, transfer, stay pending IPR, or summary judgment. The docket contains no substantive motion practice of any kind.

3. Claim construction (Markman)

• None in this case. No scheduling order, no Markman briefing, no claim construction hearing or order. (For contrast, the D.N.J. consolidated action — No. 11-3962 — did produce a claim construction opinion on 2015-04-22, D.I. 290, construing preamble language in the '219 patent.)

4. Discovery milestones

• None of record. No Rule 26(f) conference, joint discovery plan, initial disclosures, or discovery motions appear on the Delaware docket. The D.N.J. counterpart had likewise not progressed past an adjourned Rule 16 conference (set for 2016-01-26) when it was dismissed.

5. Trial, verdict, post-trial motions

• Not applicable. No trial, verdict, JMOL, new-trial, or fee motion in this action.

6. Final disposition

• 2015-12-02 — Helsinn and Roche Palo Alto file a Notice of Voluntary Dismissal as to both Par entities (D.I. 14). Because Par had never served an answer or motion for summary judgment, dismissal was available as of right under Fed. R. Civ. P. 41(a)(1)(A)(i) without a court order — a procedural detail that matters, since it means the dismissal is without prejudice and carries no merits adjudication, no preclusive effect, and no fee-shifting exposure.
• 2015-12-03 — Case terminated (FJC IDB "Date Terminated").
• 2015-12-09 — Report to the Commissioner of Patents and Trademarks (D.I. 15), closing out the file.
• 2015-12-08 — The parallel D.N.J. action (3:15-cv-02078) was dismissed by stipulation and order signed by Judge Cooper (D.N.J. D.I. 29–30; Helsinn's 2015-12-03 letter requesting dismissal). So both Delaware and New Jersey actions ended within a week of each other, contemporaneously with Par's settlement.

Strategic significance of the paired filings. The D. Del. complaint appears to have been a protective/duplicative filing made two days after the D.N.J. complaint, aimed at Par's Delaware incorporation and Roche Palo Alto's Delaware presence, while the substantive case was litigated in New Jersey (where Helsinn's U.S. affiliates and distributor Eisai sit, and where Helsinn was simultaneously litigating its ALOXI® patent family against Teva, Dr. Reddy's, and Sandoz). Delaware was the hedge; New Jersey was the forum.

Why December 2015. The dismissals followed Helsinn's decisive win in the D.N.J. consolidated action, Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., No. 11-3962 (D.N.J. 2015-11-13) — after an 11-day bench trial, Judge Cooper held the '724, '725, '424, and '219 patents valid and enforceable, and infringed by Teva's ANDA product except as to the '219/0.075 mg theory. That ruling, together with Helsinn's earlier settlements with Sandoz (dismissed 2014-12-31) and Dr. Reddy's (dismissed 2015-10-16), gave generic sponsors strong reason to settle; Par's dismissal fits that wave. Caveat: the settlement/license terms with Par are not public, and the causal link to the November 2015 ruling is my inference from timing, not a documented statement by either party.

7. Parallel PTAB proceedings and their effect

• I found no IPR, PGR, or CBM proceeding challenging U.S. Patent No. 7,947,725, and no PTAB proceeding involving Par as petitioner against Helsinn. The docket reflects no motion to stay pending IPR — consistent with there being no such petition.
• The notable PTAB activity in this drug family was a post-grant review filed by Accord Healthcare, PGR2014-00010 (filed 2014-09-02), against a related Helsinn palonosetron patent. I was not able to confirm the institution decision or final outcome of PGR2014-00010 from the sources retrieved, so I will not characterize it further. PGR was the theoretically attractive vehicle here because § 102 on-sale-bar art is available in PGR but not in IPR — a point commentators made after the Federal Circuit's Helsinn

I'll research the docket and counsel for this case.

Bottom line

Counsel of record for the plaintiffs in Helsinn Healthcare S.A. et al. v. Par Pharmaceutical Companies Inc. et al., No. 1:15-cv-00265-GMS (D. Del.) were the Morris, Nichols, Arsht & Tunnell LLP Delaware team — Jack B. Blumenfeld and Maryellen Noreika, with Karen Jacobs also appearing on the file. Helsinn's substantive/patent-side lead trial counsel in the Aloxi® ANDA program was Mark E. Waddell of Loeb & Loeb LLP (New York), though I could not confirm a formal pro hac vice appearance in this docket before it was voluntarily dismissed.

One threshold correction to the case metadata: the docket shows Roche Palo Alto LLC as a co-plaintiff with Helsinn Healthcare S.A., and the Rule 4 report lists five patents ('724, '725, '424, '219, '094) — not the '725 alone. See CourtListener docket 13252319, D.I. 4 ("Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,947,724 B2; 7,947,725 B2; 7,960,424 B2; 8,598,219 B2; 8,729,094 B2") and D.I. 14 (Notice of Voluntary Dismissal "by Helsinn Healthcare S.A., Roche Palo Alto LLC"). https://www.courtlistener.com/docket/13252319/helsinn-healthcare-sa-v-par-pharmaceutical-companies-inc/

Plaintiff-side counsel

For completeness on the defense side (not requested, but useful for the file): Stephen B. Brauerman and Sara Bussiere of Bayard, P.A. (Wilmington) were Par's Delaware counsel of record on the extension stipulations (D.I. 9–12); Par's national ANDA counsel in the parallel palonosetron matters were at Morgan, Lewis & Bockius and later Kirkland & Ellis.

Docket basis and procedural posture

• Complaint filed 3/25/2015 (D.I. 1); summons issued 3/26/2015; defendants served 7/21/2015 (D.I. 7–8).
• No answer, no motion to dismiss, no pro hac vice admissions, no motion practice — the docket runs to 15 entries, all of which are summons returns, Rule 7.1 disclosures, and four agreed extensions of Par's response deadline (D.I. 9–13).
• Plaintiffs filed a Notice of Voluntary Dismissal on 12/2/2015 (D.I. 14); patent report followed 12/9/2015 (D.I. 15). The FJC Integrated Database records the disposition as "Voluntarily dismissed" with procedural progress "No court action (before issue joined)" and termination date 12/3/2015 — consistent with the metadata's 12/2/2015 termination (date of the notice). https://www.courtlistener.com/docket/13252319/idb/helsinn-healthcare-sa-v-par-pharmaceutical-companies-inc/
• Nothing in this docket is sealed; the sparseness of the record, not sealing, is why the plaintiff-side appearance list is short. Because the case resolved pre-answer, non-Delaware counsel had no occasion to seek admission, and I found no filing in 00265 bearing a Loeb & Loeb signature or PHV motion.
• Related D. Del. filing: Helsinn Healthcare S.A. v. Hospira, Inc., No. 1:15-cv-00264-GMS (same day; associated case per the 4/1/2015 reassignment entry). A separate Par action was also filed in D.N.J., No. 3:15-cv-02078 (3/23/2015), where Helsinn's local counsel was Charles M. Lizza (Saul Ewing) — further evidence of the Morris Nichols/Loeb & Loeb + local-counsel structure of the program.

Verification caveats

1. Waddell's appearance in 00265 specifically rests on his documented role in the parallel Helsinn Delaware pleadings (13-688-GMS) and the program-wide counsel structure, not on a signature in the 00265 record. Treat his role here as "lead patent counsel for Helsinn (program-level)," not "attorney of record in 00265."
2. Young J. Park's firm is not confirmed from a primary source in my search; the PHV motion reference is from the 00264 docket as reported by CourtListener/UniCourt.
3. The docket details above come from RECAP/CourtListener and UniCourt mirrors of PACER (which can lag). The complaint's own signature block (D.I. 1) would be the definitive list, and I was unable to retrieve the D.I. 1 PDF in this session; PACER document 1 in 1:15-cv-00265 should be pulled to confirm whether Loeb & Loeb was named on the pleading.
4. Helsinn's later appellate counsel (e.g., Kannon K. Shanmugam of Williams & Connolly before the Supreme Court in Helsinn v. Teva, 586 U.S. 731 (2019)) has no connection to this 2015 Par action and should not be listed as counsel here.

Counsel of Record for the Defendant(s)

Bottom line up front: The only attorneys who appeared on the D. Del. docket for Par are two lawyers from Bayard, P.A. (Wilmington, Delaware) — i.e., local/Delaware counsel only. No national (lead) trial counsel, and no in-house counsel, ever entered an appearance in this case. That is consistent with the case's procedural history: Par never answered, never moved, and the action was voluntarily dismissed roughly eight months after filing.

Case identification note: The publicly available docket for this action is Helsinn Healthcare S.A. et al. v. Par Pharmaceutical Companies Inc. et al., No. 1:15-cv-00265 (D. Del.), filed 2015-03-25, terminated 2015-12-03, assigned to Judge Gregory M. Sleet. That docket lists five asserted patents ('724, '725, '424, '219, '094) — the prompt's metadata identifies only the '725 patent, so the two descriptions differ slightly; the '725 patent was among the patents asserted.

Supporting docket entries

• D.I. 9 (Aug. 11, 2015) — Stipulation to extend time to respond to complaint to 9/11/2015, filed by Par Pharmaceutical Companies Inc. and Par Pharmaceutical Inc., signed by Stephen Brauerman (CourtListener docket).
• D.I. 10 (Sept. 10, 2015) — Stipulation and proposed order extending Par's response to 10/12/2015, signed by Sara Bussiere.
• D.I. 12 (Nov. 13, 2015) — Joint stipulation extending response to 12/14/2015, signed by Brauerman.
• D.I. 13 (Nov. 17, 2015) — Judge Sleet order granting the extension and stating "The Court will grant no further extensions."
• D.I. 14 (Dec. 2, 2015) — Notice of voluntary dismissal by Helsinn and Roche Palo Alto as to both Par entities (signed by Karen Jacobs of Morris, Nichols, Arsht & Tunnell for plaintiffs). No answer, Rule 12 motion, or Markman activity ever occurred.
• D.I. 15 (Dec. 9, 2015) — Report to the Commissioner of Patents and Trademarks.

Party/attorney summary corroboration: UniCourt case page (lists only Brauerman as defendant attorney); DrugPatentWatch docket summary (confirming 5 patents, Judge Sleet, termination date).

What is not confirmed — and I will not guess

1. Par's national/lead trial counsel. Par was a defendant in the parallel New Jersey palonosetron litigation (Helsinn v. Par, D.N.J. No. 3:15-cv-02078, before Judge Mary L. Cooper; also the consolidated 11-3962/12-2867 actions), where a full merits defense team would have appeared. I could not verify, within this search, which firm signed Par's D.N.J. pleadings, and no such firm appeared on the Delaware docket. I therefore do not attribute any national firm to Par in this case.
2. Firm affiliations from other Par matters should not be imported. Endo/Par entities have been represented by Alston & Bird (N.D. Ohio MDL), Sterne Kessler Goldstein & Fox (S.D.N.Y.), and others in unrelated litigations. Those are different matters; nothing in the record ties them to Helsinn v. Par, D. Del. No. 15-265, so I have deliberately excluded them.
3. No in-house counsel (e.g., Endo/Par legal department) entered an appearance, and no Rule 7.1 disclosure statement was filed by Par because Par never answered.
4. Sealed material: none identified. The docket in this action consists entirely of the complaint, summons, extensions, and the voluntary dismissal; there is no sealed filing that could conceal an additional appearance.

Practical takeaway for the litigation team: if you need Par's substantive defense counsel for the palonosetron/ALOXI ANDA program, the correct place to look is the D.N.J. consolidated docket (11-3962 / 12-2867 / 15-2078) and the Federal Circuit appeal in Helsinn v. Teva, No. 16-1284 — not this short-lived Delaware case, where Bayard acted solely as Delaware counsel of record for the two Par entities.